Abstract
Systematic evaluations of the quality of research on a single prognostic biomarker are rare. We sought to evaluate the quality of prognostic research evidence for the association of C-reactive protein (CRP) with fatal and nonfatal events among patients with stable coronary disease. We searched MEDLINE (1966 to 2009) and EMBASE (1980 to 2009) and selected prospective studies of patients with stable coronary disease, reporting a relative risk for the association of CRP with death and nonfatal cardiovascular events. We included 83 studies, reporting 61,684 patients and 6,485 outcome events. No study reported a prespecified statistical analysis protocol; only two studies reported the time elapsed (in months or years) between initial presentation of symptomatic coronary disease and inclusion in the study. Studies reported a median of seven items (of 17) from the REMARK reporting guidelines, with no evidence of change over time. The pooled relative risk for the top versus bottom third of CRP distribution was 1.97 (95% confidence interval [CI] 1.78-2.17), with substantial heterogeneity (I(2) = 79.5). Only 13 studies adjusted for conventional risk factors (age, sex, smoking, obesity, diabetes, and low-density lipoprotein [LDL] cholesterol) and these had a relative risk of 1.65 (95% CI 1.39-1.96), I(2) = 33.7. Studies reported ten different ways of comparing CRP values, with weaker relative risks for those based on continuous measures. Adjusting for publication bias (for which there was strong evidence, Egger's p<0.001) using a validated method reduced the relative risk to 1.19 (95% CI 1.13-1.25). Only two studies reported a measure of discrimination (c-statistic). In 20 studies the detection rate for subsequent events could be calculated and was 31% for a 10% false positive rate, and the calculated pooled c-statistic was 0.61 (0.57-0.66). Multiple types of reporting bias, and publication bias, make the magnitude of any independent association between CRP and prognosis among patients with stable coronary disease sufficiently uncertain that no clinical practice recommendations can be made. Publication of prespecified statistical analytic protocols and prospective registration of studies, among other measures, might help improve the quality of prognostic biomarker research.
Highlights
What Is the Problem? Robust research evidence on the prognostic value of circulating biomarkers is important for translational medicine and clinical decision making, but there are concerns about the quality of such evidence [1], largely based on studies in the field of cancer
We studied C-reactive protein (CRP) in the prognosis of stable coronary artery disease because it is the most widely investigated (.100 studies) novel prognostic biomarker in such patients [7], and the research might be expected to have reached reliable conclusions
In evaluating the quality of published evidence on CRP in the prognosis of patients with stable coronary disease we carried out a systematic review, meta-analysis, and meta-regression [11,12] with five specific objectives: (i) To determine the quality of study reporting based on a systematic review
Summary
What Is the Problem? Robust research evidence on the prognostic value of circulating biomarkers is important for translational medicine and clinical decision making, but there are concerns about the quality of such evidence [1], largely based on studies in the field of cancer. We studied C-reactive protein (CRP) in the prognosis of stable coronary artery disease because it is the most widely investigated (.100 studies) novel prognostic biomarker in such patients [7], and the research might be expected to have reached reliable conclusions. We sought to evaluate the quality of prognostic research evidence for the association of C-reactive protein (CRP) with fatal and nonfatal events among patients with stable coronary disease. If plaques form in the arteries that feed the heart, the result is coronary artery disease, the symptoms of which include shortness of breath and chest pains (angina). If these symptoms only occur during exertion, the condition is called stable coronary artery disease. Narrowed arteries can be widened using a device called a stent or surgically bypassed
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have